ProMed Pharma LLC acquires SpineThera's Manufacturing Capabilities and an Option to License Intellectual Property
Acquiring Company
ProMed Pharma
Acquired Company
SpineThera, Inc.
PlymouthPlymouthManufacturingBiotechnologyPharmaceuticalBiotechnologyHealthcarePharmaceuticalDescription
ProMed Pharma LLC, a leading contract manufacturer of polymer-based drug releasing dosage forms, has acquired SpineThera’s cGMP manufacturing operational assets and obtained an option to license SpineThera’s microsphere intellectual property. This strategic acquisition allows ProMed Pharma to expand its portfolio with biodegradable microparticle development and manufacturing services, enhancing their capabilities in sustained-release drug formulations.
Quick answer
ProMed Pharma is acquiring SpineThera, Inc., announced April 3, 2024. ProMed Pharma is based in Plymouth, Minnesota, United States.
- Who acquired SpineThera, Inc?
- ProMed Pharma agreed to acquire SpineThera, Inc. on April 3, 2024.
- How much did ProMed Pharma pay for SpineThera, Inc?
- The deal value was not disclosed.
- What does ProMed Pharma do?
- ProMed Pharma LLC is a leading contract manufacturer of polymer-based drug releasing dosage forms and combination device components.
- Where are ProMed Pharma and SpineThera, Inc. based?
- ProMed Pharma is based in Plymouth, Minnesota, United States. SpineThera, Inc. is based in Plymouth, Minnesota, United States.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Healthcare
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- CoreRx, Inc. completes acquisition of Societal CDMO, Inc. to enhance drug formulation and manufacturing capabilities (April 8, 2024)
- Abbvie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases (March 25, 2024)
- IMCD Spain acquires Cobapharma, S.L.U to strengthen its Pharmaceuticals presence (April 24, 2024)
- Eli Lilly and Company acquires manufacturing facility from Nexus Pharmaceuticals to expand U.S. capacity (April 22, 2024)
- Future Pak proposes acquisition of Vanda Pharmaceuticals for $7.25 to $7.75 per share in cash (April 17, 2024)
- Century Therapeutics strengthens position in autoimmune disease through $60 Million Private Placement and Acquisition of Clade Therapeutics, $60M (April 11, 2024)
Who to call at ProMed Pharma, and when
When ProMed Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day ProMed Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ProMed Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ProMed Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ProMed Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired SpineThera, Inc.?
SpineThera, Inc. was acquired by ProMed Pharma, based in Plymouth. The deal was reported on April 3, 2024. ProMed Pharma LLC is a leading contract manufacturer of polymer-based drug releasing dosage forms and combination device components. ProMed Pharma is privately held and operates in Manufacturing.
When did ProMed Pharma acquire SpineThera, Inc.?
ProMed Pharma's acquisition of SpineThera, Inc. was reported on April 3, 2024. ProMed Pharma LLC, a leading contract manufacturer of polymer-based drug releasing dosage forms, has acquired SpineThera’s cGMP manufacturing operational assets and obtained an option to license SpineThera’s microsphere intellectual property. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does SpineThera, Inc. do?
SpineThera, Inc. is a privately held, clinical-stage pharmaceutical company focused on the development of SX600, a novel formulation of extended-release dexamethasone microspheres for epidural injection for the management of lumbar radicular pain. It is privately held, operating in Biotechnology, and is based in Plymouth.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.